In breast and gastric cancer samples, CGP failed to detect HER2 amplifications in 3/8 (37.5%) cases diagnosed with in-house testing (2/7 in breast cancer samples and 1/1 in a gastric cancer sample). Here, ERBB2 is linked to breast cancer.